Novel Medication Strategies Targeting Brain Mechanisms in Pediatric OCD
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
This study will examine the feasibility and potential efficacy of augmenting SRIs with
minocycline. The study will assess whether the addition of minocycline leads to measurable
changes in striatal glutamate (Glu) levels. This study will recruit up to 45 youth ages 8-20
diagnosed with clinically significant OCD who have demonstrated no more than minimal response
to SRI treatment and are currently on a stable dose of SRI medication for at least 12 weeks.
Participants will be randomized to receive either 12 weeks of minocycline treatment or pill
placebo. Randomization will be 2:1 so that 2 of 3 participants receive minocycline. Screening
for eligibility will take place for 1-4 weeks. Participants will undergo magnetic resonance
spectroscopy (MRS) scans to measure striatal Glu levels prior to randomization, and again
immediately following the treatment period. During the treatment period, participants will
meet initially weekly and then every other week with the study psychiatrist. All participants
will be offered three months of open medication treatment following participation. The
clinical trial will only be conducted at the New York State Psychiatric Institute (NYSPI) and
the MRS scans may be conducted at Weill Cornell Medical Center or NYSPI.
Phase:
Phase 2
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborators:
National Institute of Mental Health (NIMH) Weill Medical College of Cornell University